I’m not TYK’ed! Another TYK2 #TAK-279 in #PsA RCT. Yup it works in ballpark of other PsA #Rx. #PASI75 45.7%. No obvious dose response w 15 and 30 mg daily but more #acne at higher dose. #ACR23 @ACRheum @RheumNow poster L12 Where to use vs #Deucravitinib? Too early to say as Ph2 https://t.co/nMkgOlUf6s

Interesting question... but feels like some time related bias or perhaps confounding? Seems implausible that MTX & biologic would be protective for PsO & harmful for PsA @RheumNow #ACR23 Abstr 0498 https://t.co/pSRoLHRTAm

Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS

#ACR23 Abs #0505 found use of IL-17 inhibitors and oral DMARD alone were associated with a decreased likelihood of achieving MDA in PsA. Small sample size, but interesting finding nonetheless. https://t.co/CAZGykwxRT @rheumnow https://t.co/8ptF8aTIFu

How can we maximise digital health to improve outcomes. Come and visit my poster session today and it will be good to meet IRL. I’m presenting poster #0507 using digital e-PROMs to measure disease activity in psoriatic arthritis #digital Abst #0507 #ACR23 @RheumNow https://t.co/R9LX8H9X0E

#ACR23 Abs 0484 found higher hs-CRP levels helped identify PsO pts at high risk of future development of PsA. Unclear timeline, but this may help to early ID referrals to rheum. https://t.co/4JRsI6iEgI @rheumnow https://t.co/sXNwyL87Ud

Pain, itch, and fatigue associated with decreased work productivity/impairment in PsA and PsO pts. #ACR23 considerations for treatment for these pts should include these factors. Abs #0488 https://t.co/mLG5ohFopQ @rheumnow https://t.co/8ANL4pcxM2

Different plant products We need more RCTs Cohort studies have a lot of attrition Survey data shows increased utilization #ACR23 @RheumNow https://t.co/H2pOEJ99Qh